Virology
September 9, 2020

Virology Placeholder post

(Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)
Read More
brain_imagination-2560x1440
NASH
August 27, 2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

(Oral presentation, EASL International Liver Congress, 27-29 August 2020, Abstract #AS074)
Read More
NASH
August 27, 2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

(Poster, EASL International Liver Congress, 27-29 August 2020, Abstract #SAT038)
Read More
PRESS RELEASES
June 17, 2020

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Oral FASN inhibitor TVB-2640 significantly reduces liver fat with a 61% responder rate Demonstrates improvement in markers of liver function and fibrosis Results to be presented on August 28 at…
Read More
PRESS RELEASES
March 31, 2020

Data on Sagimet’s Lead Candidate TVB-2640 to be Presented at EASL ILC 2020

Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology…
Read More
NASH
December 18, 2019

First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities

(Paper, Hepatology 2020)
Read More
Uncategorized
September 24, 2019

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Read More
Uncategorized
September 24, 2019

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush…
Read More
NASH
September 6, 2019

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

(Poster, Obesity Week, 11-15 November 2018, Abstract # T-P-3383)
Read More
NASH
September 5, 2019

The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model

(Poster, AASLD The Liver Meeting, 9-13 November 2018, Abstract #734)
Read More